

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014033 A1

(51) International Patent Classification⁷: **A61K 38/25,**
38/27, 38/30, 48/00, A61P 25/16

(21) International Application Number:
PCT/EP2003/050348

(22) International Filing Date: **29 July 2003 (29.07.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(71) Applicant (for all designated States except US): **ARES
TRADING S.A. [CH/CH]; Zone Industrielle de l'Ourietaz,
CH-1170 Aubonne (CH).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BENGTSSON,
Bengt-Ake [SE/SE]; Hägnegårdsvägen 10, S-43632
Askim (SE).**

(74) Agent: **SERONO INTERNATIONAL S.A. INTEL-
LECTUAL PROPERTY; 12, Chemin des Aulx, CH-1228
Plan-les-Ouates (CH).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **USE OF HUMAN GROWTH HORMONE IN MULTIPLE SYSTEM ATROPHY**

(57) Abstract: The invention relates to the use of a substance, which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance, which stimulates release or potentiates the activity of endogenous hGH, for treatment and/or prevention of Parkinsonism-Plus Syndromes. In particular, the invention relates to the use of hGH for the treatment and/or prevention of Multiple System Atrophy.



WO 2005/014033 A1